Monday, May 16, 2022 3:39:45 PM
An example is a drug courier. If you were driving to a restaurant with a friend and they stopped across the street from a UPS store and asked if you could run in and pick up a package for them because they were in a No Parking zone, you probably wouldn't think anything of it. However, if someone you barely knew offered you $50 if you would drive with them to a UPS store and you would go in and get a package and then return to the car, you would think that there was probably something illegal in that package for them to offer you a bunch of money for something they could easily do themselves for free.
In our case, the clinicaltrials.gov website, which is believed to be updateable by the company, states that the primary endpoint of the trial is PFS. If the company is claiming the endpoint is changed, then why haven't they changed it in the 19 months since the trial ended because you can't change it after data-lock? So it is reasonable for shorts to claim that the endpoints have not changed. Likewise, the fact that cross-over patients seem to do better than DC Vax-L patients requires some additional explanation. Hence why they need to have a journal article.
So yeah, maybe if they had done everything right, this all still would have fallen apart but then there would have been actual evidence of malicious intent and bad faith. Instead we are in a squishy grey area that no one is likely to touch. When the Washington Post piece came out several years back, other news organizations came to AF's defense. Without actual evidence of a crime, suggesting a journalist committed a crime is not a good move.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM